{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:06:50Z","timestamp":1794956810203,"version":"4.9.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2015-00799"],"award-info":[{"award-number":["2015-00799"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003173","name":"Crafoord Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sk\u00e5ne Regional Council"},{"name":"The K\u00f6nigska Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ketamine has emerged as a fast-acting and powerful antidepressant, but no head to head trial has been performed, Here, ketamine is compared with electroconvulsive therapy (ECT), the most effective therapy for depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Hospitalized patients with unipolar depression were randomized (1:1) to thrice-weekly racemic ketamine (0.5 mg\/kg) infusions or ECT in a parallel, open-label, non-inferiority study. The primary outcome was remission (Montgomery \u00c5sberg Depression Rating Scale score \u226410). Secondary outcomes included adverse events (AEs), time to remission, and relapse. Treatment sessions (maximum of 12) were administered until remission or maximal effect was achieved. Remitters were followed for 12 months after the final treatment session.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total 186 inpatients were included and received treatment. Among patients receiving ECT, 63% remitted compared with 46% receiving ketamine infusions (P\u2009=\u2009.026; difference 95% CI 2%, 30%). Both ketamine and ECT required a median of 6 treatment sessions to induce remission. Distinct AEs were associated with each treatment. Serious and long-lasting AEs, including cases of persisting amnesia, were more common with ECT, while treatment-emergent AEs led to more dropouts in the ketamine group. Among remitters, 70% and 63%, with 57 and 61 median days in remission, relapsed within 12 months in the ketamine and ECT groups, respectively (P\u2009=\u2009.52).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Remission and cumulative symptom reduction following multiple racemic ketamine infusions in severely ill patients (age 18\u201385 years) in an authentic clinical setting suggest that ketamine, despite being inferior to ECT, can be a safe and valuable tool in treating unipolar depression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyab088","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T07:37:30Z","timestamp":1638517050000},"page":"339-349","source":"Crossref","is-referenced-by-count":109,"title":["Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT)"],"prefix":"10.1093","volume":"25","author":[{"given":"Joakim","family":"Ekstrand","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fattah","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Persson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine, Lund University , Helsingborg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine, Lund University , Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Nordanskog","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Link\u00f6ping University , Link\u00f6ping , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"\u00c5keson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine, Lund University , Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Tingstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats B","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine, Lund University , Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-3065","authenticated-orcid":false,"given":"Axel","family":"Nordenskj\u00f6ld","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2041-3550","authenticated-orcid":false,"given":"Pouya","family":"Movahed Rad","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Faculty of Medicine, Lund University , Lund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"key":"2022053117543519600_CIT0001","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol Psychiatry"},{"key":"2022053117543519600_CIT0002","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"2022053117543519600_CIT0003","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J Trauma Stress"},{"key":"2022053117543519600_CIT0004","first-page":"CD011612","article-title":"Ketamine and other glutamate receptor modulators for depression in adults","volume":"9","author":"Caddy","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2022053117543519600_CIT0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0004867416631828","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation","volume":"51","author":"Cusin","year":"2017","journal-title":"Aust N Z J Psychiatry"},{"key":"2022053117543519600_CIT0006","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol Psychiatry"},{"key":"2022053117543519600_CIT0007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jad.2017.06.043","article-title":"Low-dose ketamine for treatment resistant depression in an academic clinical practice setting","volume":"221","author":"Feifel","year":"2017","journal-title":"J Affect Disord"},{"key":"2022053117543519600_CIT0008","doi-asserted-by":"crossref","DOI":"10.1017\/9781911623175","volume-title":"The ECT handbook","author":"Ferrier","year":"2019","edition":"4"},{"key":"2022053117543519600_CIT0009","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)61340-X","article-title":"Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990\u20132013: quantifying the epidemiological transition","volume":"386","author":"GBD 2013 DALYs and HALE Collaborators","year":"2015","journal-title":"Lancet"},{"key":"2022053117543519600_CIT0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11920-016-0674-5","article-title":"Electroconvulsive therapy in the elderly: new findings in geriatric depression","volume":"18","author":"Geduldig","year":"2016","journal-title":"Curr Psychiatry Rep"},{"key":"2022053117543519600_CIT0011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.psychres.2013.12.008","article-title":"Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder","volume":"215","author":"Ghasemi","year":"2014","journal-title":"Psychiatry Res"},{"key":"2022053117543519600_CIT0012","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4088\/JCP.v65n0406","article-title":"Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report","volume":"65","author":"Husain","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"2022053117543519600_CIT0013","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1192\/bjp.bp.109.066183","article-title":"Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial","volume":"196","author":"Kellner","year":"2010","journal-title":"Br J Psychiatry"},{"key":"2022053117543519600_CIT0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-publhealth-031912-114409","article-title":"The epidemiology of depression across cultures","volume":"34","author":"Kessler","year":"2013","journal-title":"Annu Rev Public Health"},{"key":"2022053117543519600_CIT0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jad.2015.12.067","article-title":"Mortality and life expectancy in persons with severe unipolar depression","volume":"193","author":"Laursen","year":"2016","journal-title":"J Affect Disord"},{"key":"2022053117543519600_CIT0016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/acps.12572","article-title":"Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression","volume":"134","author":"Loo","year":"2016","journal-title":"Acta Psychiatr Scand"},{"key":"2022053117543519600_CIT0017","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2022053117543519600_CIT0018","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol Psychiatry"},{"key":"2022053117543519600_CIT0019","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"2022053117543519600_CIT0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1385\/1-59259-165-5:199","article-title":"NMDA antagonist-induced neurotoxicity and psychosis.","volume-title":"Handbook of neurotoxicology","author":"Noghuchi","year":"2002"},{"key":"2022053117543519600_CIT0021","first-page":"470985","article-title":"Predictors of time to relapse\/recurrence after electroconvulsive therapy in patients with major depressive disorder: a population-based cohort study","volume":"2011","author":"Nordenskjold","year":"2011","journal-title":"Depress Res Treat"},{"key":"2022053117543519600_CIT0022","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"2022053117543519600_CIT0023","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/pcn.12675","article-title":"Time until relapse after augmentation with single-dose ketamine in treatment-resistant depression","volume":"72","author":"Perez-Esparza","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"2022053117543519600_CIT0024","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0269881113478283","article-title":"Serial infusions of low-dose ketamine for major depression","volume":"27","author":"Rasmussen","year":"2013","journal-title":"J Psychopharmacol"},{"key":"2022053117543519600_CIT0025","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2022053117543519600_CIT0026","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biopsych.2010.06.009","article-title":"Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis","volume":"68","author":"Semkovska","year":"2010","journal-title":"Biol Psychiatry"},{"key":"2022053117543519600_CIT0027","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S1461145714001011","article-title":"Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression","volume":"17","author":"Shiroma","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"2022053117543519600_CIT0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2022053117543519600_CIT0029","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am J Psychiatry"},{"key":"2022053117543519600_CIT0030","first-page":"287","article-title":"Relationship of ketamine\u2019s antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuro Endocrinol Lett"},{"key":"2022053117543519600_CIT0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/JCP.0000000000000090","article-title":"Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder","volume":"34","author":"Szymkowicz","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"2022053117543519600_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10401230601163360","article-title":"Relapse during continuation pharmacotherapy after acute response to ECT: a comparison of usual care versus protocolized treatment","volume":"19","author":"Tew","year":"2007","journal-title":"Ann Clin Psychiatry"},{"key":"2022053117543519600_CIT0033","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jad.2016.09.008","article-title":"Continuation phase intravenous ketamine in adults with treatment-resistant depression","volume":"206","author":"Vande Voort","year":"2016","journal-title":"J Affect Disord"},{"key":"2022053117543519600_CIT0034","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JCP.0000000000000960","article-title":"Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg\/kg in treatment-resistant major depression: an open 4-week longitudinal study","volume":"38","author":"Vidal","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"2022053117543519600_CIT0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000457960","article-title":"Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression","volume":"86","author":"Wilkinson","year":"2017","journal-title":"Psychother Psychosom"},{"key":"2022053117543519600_CIT0036","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyab088\/42136943\/pyab088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyab088\/43846938\/pyab088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyab088\/43846938\/pyab088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T15:40:17Z","timestamp":1654011617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/25\/5\/339\/6451171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,4]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,12,4]]},"published-print":{"date-parts":[[2022,5,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyab088","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,12,4]]}}}